{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:55:17Z","timestamp":1757613317200,"version":"3.44.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,4]]},"DOI":"10.7759\/cureus.91618","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T19:45:50Z","timestamp":1757015150000},"source":"Crossref","is-referenced-by-count":0,"title":["Description of a National Cohort of Patients With Left Atrial Appendage Occlusion Devices"],"prefix":"10.7759","author":[{"given":"Zhe","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan G","family":"Kane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.8.939","article-title":"Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment","volume":"89","author":"Markides V","year":"2003","unstructured":"Markides V, Schilling RJ. Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. Heart. 2003, 89:939-43. 10.1136\/heart.89.8.939","journal-title":"Heart"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2174\/1573403x10666140902143020","article-title":"How does chronic atrial fibrillation influence mortality in the modern treatment era?","volume":"11","author":"Sankaranarayanan R","year":"2015","unstructured":"Sankaranarayanan R, Kirkwood G, Visweswariah R, Fox DJ. How does chronic atrial fibrillation influence mortality in the modern treatment era?. Curr Cardiol Rev. 2015, 11:190-8. 10.2174\/1573403x10666140902143020","journal-title":"Curr Cardiol Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcy088","article-title":"Clinical significance of atrial kick","volume":"111","author":"Namana V","year":"2018","unstructured":"Namana V, Gupta SS, Sabharwal N, Hollander G. Clinical significance of atrial kick. QJM. 2018, 111:569-70. 10.1093\/qjmed\/hcy088","journal-title":"QJM"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2024.07.004","article-title":"Predictors of paroxysmal atrial fibrillation in patients with a cryptogenic stroke: selecting patients for long-term rhythm monitoring","volume":"22","author":"Apple SJ","year":"2025","unstructured":"Apple SJ, Parker M, Flomenbaum D, et al.. Predictors of paroxysmal atrial fibrillation in patients with a cryptogenic stroke: selecting patients for long-term rhythm monitoring. Heart Rhythm. 2025, 22:13-20. 10.1016\/j.hrthm.2024.07.004","journal-title":"Heart Rhythm"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.15420\/aer.2015.04.02.100","article-title":"Anticoagulation in atrial fibrillation - current concepts","volume":"4","author":"Katritsis DG","year":"2015","unstructured":"Katritsis DG, Gersh BJ, Camm AJ. Anticoagulation in atrial fibrillation - current concepts. Arrhythm Electrophysiol Rev. 2015, 4:100-7. 10.15420\/aer.2015.04.02.100","journal-title":"Arrhythm Electrophysiol Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.09.030","article-title":"Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation","volume":"125","author":"Mason PK","year":"2012","unstructured":"Mason PK, Lake DE, DiMarco JP, et al.. Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. Am J Med. 2012, 125:603.e1-6. 10.1016\/j.amjmed.2011.09.030","journal-title":"Am J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip GY","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010, 137:263-72. 10.1378\/chest.09-1584","journal-title":"Chest"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm AJ","year":"2010","unstructured":"Camm AJ, Kirchhof P, Lip GY, et al.. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010, 31:2369-429. 10.1093\/eurheartj\/ehq278","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.590257","article-title":"Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort","volume":"41","author":"Lip GY","year":"2010","unstructured":"Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010, 41:2731-8. 10.1161\/STROKEAHA.110.590257","journal-title":"Stroke"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu298","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)","volume":"35","author":"Lip GY","year":"2014","unstructured":"Lip GY, Windecker S, Huber K, et al.. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014, 35:3155-79. 10.1093\/eurheartj\/ehu298","journal-title":"Eur Heart J"},{"key":"ref11","article-title":"Anatomy, thorax, heart left atrial appendage","author":"Arora Y","year":"2023","unstructured":"Arora Y, Jozsa F, Soos MP. Anatomy, thorax, heart left atrial appendage. StatPearls. StatPearls Publishing, Treasure Island; 2023."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034187","article-title":"Thrombogenic and arrhythmogenic roles of the left atrial appendage in atrial fibrillation","volume":"138","author":"Di Biase L","year":"2018","unstructured":"Di Biase L, Natale A, Romero J. Thrombogenic and arrhythmogenic roles of the left atrial appendage in atrial fibrillation. Circulation. 2018, 138:2036-50. 10.1161\/CIRCULATIONAHA.118.034187","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-014-9565-5","article-title":"Left atrial appendage devices for stroke prevention in atrial fibrillation","volume":"7","author":"Hussain SK","year":"2014","unstructured":"Hussain SK, Malhotra R, DiMarco JP. Left atrial appendage devices for stroke prevention in atrial fibrillation. J Cardiovasc Transl Res. 2014, 7:458-64. 10.1007\/s12265-014-9565-5","journal-title":"J Cardiovasc Transl Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.04.067","article-title":"Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation","volume":"75","author":"Osmancik P","year":"2020","unstructured":"Osmancik P, Herman D, Neuzil P, et al.. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. J Am Coll Cardiol. 2020, 75:3122-35. 10.1016\/j.jacc.2020.04.067","journal-title":"J Am Coll Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes DR Jr","year":"2014","unstructured":"Holmes DR Jr, Kar S, Price MJ, et al.. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014, 64:1-12. 10.1016\/j.jacc.2014.04.029","journal-title":"J Am Coll Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.15192","article-title":"Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial","volume":"312","author":"Reddy VY","year":"2014","unstructured":"Reddy VY, Sievert H, Halperin J, et al.. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014, 312:1988-98. 10.1001\/jama.2014.15192","journal-title":"JAMA"},{"key":"ref17","unstructured":"How Epic\u2019s Cosmos supported clinical research with de-identified data. (2022). Accessed. November 5, 2024: https:\/\/www.techtarget.com\/searchhealthit\/answer\/How-Epics-Cosmos-Supported-Clinical-Research-with-De-Identified-Data."},{"key":"ref18","unstructured":"About Cosmos. (2024). Accessed. November 5, 2024: https:\/\/cosmos.epic.com\/about\/."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.47912\/jscdm.246","article-title":"Cosmos: real-world data powered by the healthcare community","volume":"3","author":"Noel A","year":"2023","unstructured":"Noel A, Bartelt K. Cosmos: real-world data powered by the healthcare community. J Soc Clin Data Manag. 2023, 3:10.47912\/jscdm.246","journal-title":"J Soc Clin Data Manag"},{"key":"ref20","unstructured":"Cosmos. (2025). Accessed. March 20, 2025: https:\/\/cosmos.epic.com\/."},{"key":"ref21","article-title":"An IRB\u2019s Perspective on Epic\u2019s Cosmos","author":"Cobb N","year":"2018","unstructured":"Cobb N. An IRB\u2019s Perspective on Epic\u2019s Cosmos. University of Wisconsin-Madison, Madison; 2018."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg L","year":"2012","unstructured":"Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012, 33:1500-10. 10.1093\/eurheartj\/ehr488","journal-title":"Eur Heart J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2024.09.059","article-title":"Epidemiology of heart failure presentations to United States emergency departments from 2016 to 2023","volume":"86","author":"Gottlieb M","year":"2024","unstructured":"Gottlieb M, Moyer E, Bernard K. Epidemiology of heart failure presentations to United States emergency departments from 2016 to 2023. Am J Emerg Med. 2024, 86:70-3. 10.1016\/j.ajem.2024.09.059","journal-title":"Am J Emerg Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2024.10.002","article-title":"Diverticulitis evaluation and management among United States emergency departments over an eight-year period","volume":"86","author":"Gottlieb M","year":"2024","unstructured":"Gottlieb M, Wusterbarth E, Moyer E, Bernard K. Diverticulitis evaluation and management among United States emergency departments over an eight-year period. Am J Emerg Med. 2024, 86:83-6. 10.1016\/j.ajem.2024.10.002","journal-title":"Am J Emerg Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2024.09.016","article-title":"Epidemiology of pulmonary embolism diagnosis and management among United States emergency departments over an eight-year period","volume":"85","author":"Gottlieb M","year":"2024","unstructured":"Gottlieb M, Moyer E, Bernard K. Epidemiology of pulmonary embolism diagnosis and management among United States emergency departments over an eight-year period. Am J Emerg Med. 2024, 85:158-62. 10.1016\/j.ajem.2024.09.016","journal-title":"Am J Emerg Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4997\/JRCPE.2020.409","article-title":"Retrospective studies - utility and caveats","volume":"50","author":"Talari K","year":"2020","unstructured":"Talari K, Goyal M. Retrospective studies - utility and caveats. J R Coll Physicians Edinb. 2020, 50:398-402. 10.4997\/JRCPE.2020.409","journal-title":"J R Coll Physicians Edinb"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-085081","article-title":"Demographic and clinical characteristics of New York City Health + Hospitals HIV Heart Failure (NYC4H cohort): cohort profile","volume":"14","author":"Chen YY","year":"2024","unstructured":"Chen YY, Borkowski P, Nazarenko N, et al.. Demographic and clinical characteristics of New York City Health + Hospitals HIV Heart Failure (NYC4H cohort): cohort profile. BMJ Open. 2024, 14:e085081. 10.1136\/bmjopen-2024-085081","journal-title":"BMJ Open"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2023.07.015","article-title":"5-year stroke rates in nonvalvular atrial fibrillation after watchman compared to direct oral anticoagulants","volume":"83","author":"Khalid SI","year":"2024","unstructured":"Khalid SI, Sathianathan S, Thomson KB, McGuire LS, Soni MC, Mehta AI. 5-year stroke rates in nonvalvular atrial fibrillation after watchman compared to direct oral anticoagulants. J Cardiol. 2024, 83:163-8. 10.1016\/j.jjcc.2023.07.015","journal-title":"J Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.067599","article-title":"One-year outcomes after Amulet or Watchman device for percutaneous left atrial appendage closure: a prespecified analysis of the SWISS-APERO randomized clinical trial","volume":"149","author":"Galea R","year":"2024","unstructured":"Galea R, Meneveau N, De Marco F, et al.. One-year outcomes after Amulet or Watchman device for percutaneous left atrial appendage closure: a prespecified analysis of the SWISS-APERO randomized clinical trial. Circulation. 2024, 149:484-6. 10.1161\/CIRCULATIONAHA.123.067599","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/373224-description-of-a-national-cohort-of-patients-with-left-atrial-appendage-occlusion-devices","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T19:45:52Z","timestamp":1757015152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/373224-description-of-a-national-cohort-of-patients-with-left-atrial-appendage-occlusion-devices"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.91618","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,9,4]]}}}